EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antiretroviral Therapy

Roy M Gulick iD

New England Journal of Medicine · 23.07.2026 · 395 (4) · 374-387

DOI: 10.1056/nejmra2511692 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, erschienen am 23.07.2026. Verfasst von Roy M Gulick. Beteiligte Einrichtung: Weill Cornell Medicine, New York. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of effective treatment strategies for human immunodeficiency virus (HIV) infection is a major achievement. Antiretroviral drugs inhibit key steps in the viral replication cycle and consist of six mechanistic classes: HIV entry inhibitors, reverse-transcriptase inhibitors (both nucleosides and nonnucleosides), capsid inhibitors, integrase inhibitors, and protease inhibitors. Antiretroviral therapy (ART) suppresses viral replication, thereby enhancing immune function, decreasing morbidity and mortality, and preventing viral transmission. Consequently, ART is recommended for all persons with HIV infection. On the basis of randomized clinical trials, the Food and Drug Administration has approved 36 antiretroviral drugs for the treatment of HIV infection since 1987; of these, 28 are currently available in the United States, and combination ART regimens are used. Initial preferred ART regimens are potent, convenient, and unlikely to cause side effects and consist of an HIV integrase inhibitor with a high barrier to resistance combined with one or two nucleoside reverse-transcriptase inhibitors. In the majority of patients using current ART regimens, viral replication is durably suppressed below detectable levels. Patients receiving ART are monitored for virologic response over time, and if virologic failure occurs, the next regimen is selected on the basis of treatment history and the results of drug-resistance testing; often, antiretroviral drugs from new classes are administered. Today, the life expectancy of someone with HIV infection who consistently takes ART approaches that of the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsHumansDrug Resistance, ViralDrug Therapy, CombinationHIV Integrase InhibitorsHIV-1Reverse Transcriptase InhibitorsVirus ReplicationVirus InternalizationHIV Protease InhibitorsRandomized Controlled Trials as TopicUnited StatesDrug ApprovalUnited States Food and Drug AdministrationLife Expectancy

Substanzen

Anti-HIV AgentsHIV Integrase InhibitorsReverse Transcriptase InhibitorsHIV Protease Inhibitors

Autor:innen und Institutionen

  • Weill Cornell Medicine, New York.

ORCID-Profile: Roy M Gulick

Zitieren

APA

Gulick, R. M. (2026). Antiretroviral Therapy. New England Journal of Medicine, 395(4), 374-387. https://doi.org/10.1056/nejmra2511692

Vancouver

Gulick RM. Antiretroviral Therapy. New England Journal of Medicine. 2026;395(4):374-387. doi:10.1056/nejmra2511692

BibTeX
@article{Gulick2026,
  author = {Gulick, Roy M},
  title = {Antiretroviral Therapy},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {4},
  pages = {374--387},
  doi = {10.1056/nejmra2511692}
}
Kostenlos starten →